Electrophysiology Devices And Equipment Market Definition

Electrophysiology devices and equipment are used in the diagnosis and treatment of heart rhythm disorders through electrical activity. The main product types in the electrophysiology devices and equipment are electrophysiology ablation catheters, electrophysiology diagnostic catheters, and electrophysiology lab systems. Electrophysiology ablation catheters measure the electrical activity of the heart and diagnose abnormal heart rhythm. The various monitoring devices involved are electrocardiograph (ECG), electroencephalograph (EEG), electrocorticography (ECoG), electromyography (EMG), electroretinographic (ERG), electrooculography (EOG), Holter monitoring devices, X-ray systems, imaging and 3D mapping systems, and diagnostic electrophysiology catheters that are used in indication analysis of atrioventricular nodal reentry tachycardia (AVERT), Wolff-Parkinson-white syndrome (WPW), atrial flutter, and atrial fibrillation. The various end-users of electrophysiology devices and equipment are used in hospitals, diagnostic centers, and clinics.

Electrophysiology Devices And Equipment Market Segmentation

The electrophysiology devices and equipment market covered in this report is segmented – 1) By Product Type: Electrophysiology Ablation Catheters, Electrophysiology Diagnostic Catheters, Electrophysiology Lab Systems 2) By Monitoring Device Type: Electrocardiograph (ECG), Electroencephalograph (EEG), Electrocorticograph (ECoG), Electromyograph (EMG), Electroretinograph (ERG), Electrooculograph (EOG), Holter Monitoring Devices, X-Ray Systems, Imaging and 3D Mapping Systems, Diagnostic Electrophysiology Catheters 3) By Indication Analysis: Atrioventricular Nodal Reentry Tachycardia (AVNRT), Wolff-Parkinson-White Syndrome (WPW), Atrial Flutter, Atrial Fibrillation 4) By End-Users: Hospitals, Diagnostic centers, Clinics

Neurostimulation Devices Market Definition

Neurostimulation devices are implantable and programmable medical devices that send low voltage electricity to a specific nerve or target in the spinal cord or brain to affect neuronal transmissions. This procedure is used to treat or modulate motor functions in conditions such as neuropathic pain, chronic pain, major treatment-resistant depression Parkinson’s disease, epilepsy, incontinence, gastroparesis, and essential tremor. The main products of the neurostimulation devices are implantable devices and external devices. The implantable devices involved are cochlear implants, deep brain stimulation; spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation and the external devices are transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). The various applications of implantable devices are pain management, epilepsy, essential tremor, urinary and fecal incontinence, depression, dystonia, gastroparesis, and Parkinson's disease that are used by various end-users such as hospitals, rehabilitation centres, and medical clinics.

Neurostimulation Devices Market Segmentation

The neurostimulation devices market covered in this report is segmented – 1) By Product: Implantable Devices, External Devices 2) By Application: Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease 3) By End User: Hospitals, Rehabilitation Centers, Medical Clinic Sub-Segments Covered: By Implantable Devices: Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation 5) By External Devices: Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)

Neurodegenerative Disorder Therapeutics Market Definition

Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacy, retail pharmacy, and online pharmacy.

Neurodegenerative Disorder Therapeutics Market Segmentation

The neurodegenerative disorder therapeutics market covered in this report is segmented – 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Brain And Neuroimaging Devices Market Definition

Brain and neuroimaging devices are medical devices used to capture the structure, function, or pharmacology of the brain and locate areas affected by neurological disorders. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography (PET) is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers.

Brain And Neuroimaging Devices Market Segmentation

The brain and neuroimaging devices market covered in this report is segmented – 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types 2) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications 3) By End-user: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres

Brain Monitoring Market Definition

Brain monitoring refers to a set of continuous online monitoring, which substantially measures the particle velocity of cerebral blood flow and volume wave in the brain. Brain monitoring is used for individualized patient management such as brain and neuro-related diagnostics and treatment purposes. The main product types in brain monitoring are magnetoencephalography, electroencephalography, cerebral oximeters, functional magnetic resonance imaging (fMRI), intracranial pressure monitoring devices, and others. Magnetoencephalography refers to the noninvasive technique that detects and records the magnetic field associated with electrical activity in the brain. The procedures used are invasive and non-invasive. The applications involved are Parkinson’s disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and others. The various end-users involved are hospitals and clinics, neurology centers, ambulatory surgery centers, diagnostic centers, and others.

Brain Monitoring Market Segmentation

The brain monitoring market covered in this report is segmented – 1) By Product: Magnetoencephalograph, Electroencephalograph, Cerebral Oximeters, Functional Magnetic Resonance Imaging (fMRI), Intracranial Pressure Monitoring Devices, Other Product Types 2) By Procedure: Invasive, Non-invasive 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications 4) By End User: Hospitals and Clinics, Neurology Centres, Ambulatory Surgery Centers, Diagnostic Centers, Other End Users

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. CNS disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities The main types of central nervous system (CNS) drugs are analgesics, anti-parkinson drugs, anesthetics, anti-epileptics and other CNS drugs. Analgesics, also known as painkillers, are medications that alleviate various types of pain, ranging from headaches to injuries to arthritis. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global central nervous system drugs market size is expected to grow from $169.11 billion in 2021 to $178.70 billion in 2022 at a compound annual growth rate (CAGR) of 5.7%. The growth in the CNS drugs market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The central nervous system drugs market is expected to reach $264.97 billion in 2026 at a CAGR of 10.3%. The central nervous system drugs market will be driven by rapid growth in emerging markets in the forecast period. Emerging markets growth is aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020., according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth will boost the demand for central nervous system drugs and this will drive the market during the forecast period. During the forecast period, the growth of the central nervous system drugs market will be restrained by patent expiration of branded central nervous system drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics drugs manufacturers broaden their products and services. For instance, in March 2021, SEQENS and Rondol Group had announced a collaboration in formulation research and continuous flow manufacturing for existing, repurposed, or new drugs for oncology, infectious diseases, and central nervous system disorders. In June 2021, DSM and Brains Bioceutical have established a global exclusive partnership to unlock the therapeutic potential of cannabinoids in early-stage drug development. The cannabinoid API market is rapidly expanding, fueled by strong scientific evidence demonstrating cannabinoid's potential in a variety of therapeutic areas, including Central Nervous System (CNS) diseases. Major companies in the central nervous system drugs market include Biogen Inc, Johnson & Johnson, Novartis AG, UCB S.A., Takeda Pharmaceuticals, AbbVie, Teva Pharmaceuticals, GlaxosmithKline, Daiichi Sankyo Company and H Lundbeck. North America was the largest region in the central nervous system drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the CNS drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the central nervous system drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global central nervous system drugs market is segmented - 1) By Type: Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Other CNS Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs